Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxaglip...